Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asahi Intecc CoFRA:6XT -4.00%97 Debt-to-EBITDA is 0.12 as of Dec. 2025, which is 73% below its 10-year median of 0.45. GuruFocus rates FRA:6XT with a GF Score™ of 97/100 and a GF Value™ of €17.27 (Modestly Overvalued). Among 469 Medical Devices & Instruments companies, Asahi Intecc Co ranks better than 87.85% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Asahi Intecc Co's Debt-to-EBITDA or its related term are showing as below:
FRA:6XT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13 Med: 0.45 Max: 0.82
Current: 0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Asahi Intecc Co was 0.82. The lowest was 0.13. And the median was 0.45.
FRA:6XT's Debt-to-EBITDA is ranked better than 87.85% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs FRA:6XT: 0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Asahi Intecc Co Debt-to-EBITDA Related Terms
Asahi Intecc Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Asahi Intecc Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XT vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Asahi Intecc Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asahi Intecc Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asahi Intecc Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Asahi Intecc Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Asahi Intecc Co (FRA:6XT) has a Debt-to-EBITDA of 0.12 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asahi Intecc Co. This is 73% below median its historical median of 0.45. Over the past decade, Asahi Intecc Co's Debt-to-EBITDA has ranged from 0.13 to 0.82. According to the industry distribution chart, Asahi Intecc Co ranks #57 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 12.2%.
Is Asahi Intecc Co's Debt-to-EBITDA too high?
Asahi Intecc Co's current Debt-to-EBITDA of 0.12 is 73% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.82. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Asahi Intecc Co's value of 0.12 is 92.5% below this industry median. Based on the distribution chart, Asahi Intecc Co ranks #57 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Asahi Intecc Co has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asahi Intecc Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Asahi Intecc Co ranks #57 out of 469 companies for Debt-to-EBITDA. This places Asahi Intecc Co in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.60. Asahi Intecc Co's value of 0.12 is 92.5% below this benchmark. Historically, Asahi Intecc Co's own Debt-to-EBITDA has ranged from 0.13 to 0.82 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 1.60, Asahi Intecc Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asahi Intecc Co's current Debt-to-EBITDA of 0.12 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asahi Intecc Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asahi Intecc Co's current Debt-to-EBITDA is 0.12, which is 73% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asahi Intecc Co stock overvalued right now?
Based on GuruFocus' analysis, Asahi Intecc Co (FRA:6XT) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.27, compared to a current price of €19.20 — trading 11.2% above its estimated fair value. The current Debt-to-EBITDA is 0.12, which is 73% below median its 10-year median of 0.45 and 92.5% below the Medical Devices & Instruments industry median of 1.60. Asahi Intecc Co's overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Asahi Intecc Co (FRA:6XT), the current Debt-to-EBITDA is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asahi Intecc Co (FRA:6XT) Overvalued in 2026?
Based on GuruFocus' analysis, Asahi Intecc Co stock appears to be overvalued.
The current stock price of €19.20 is trading 11.2% above its estimated GF Value™ of €17.27.
GuruFocus considers Asahi Intecc Co to be Modestly Overvalued.
Key valuation signals for FRA:6XT:
Debt-to-EBITDA: 0.12 (73% below median its 10-year median of 0.45)
GF Value™: €17.27 vs. price of €19.20 (11.2% above fair value)
Industry Position: 92.5% below the Medical Devices & Instruments median (#57 of 469)
No single metric tells the full story. See the FRA:6XT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asahi Intecc Co Ltd is engaged in the development, manufacturing, and sales of medical and industrial equipment components. The company operates through two reportable segments: Medical Business and Device Business. The Medical Business develops, manufactures, and sells proprietary and OEM products in the medical equipment field, while the Device Business focuses on components for medical and industrial equipment applications. It generates the majority of its revenue from the Medical Business segment.
97GF Score
Get the complete analysis for FRA:6XT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XT has been successfully added to your 
